ibritumomab tiuxetan

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
ibritumomab tiuxetan

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®

ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))

Compound class: Antibody

Comment: A monoclonal antibody used as a radioimmunotherapy treatment.

No information available.

No information available.

Summary of Clinical Use
Used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (labelled with the high energy beta emitter, Yttrium-90). Can be labelled with Indium-111 for diagnostic investigation/imaging.

Summary of Clinical Use

Used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (labelled with the high energy beta emitter, Yttrium-90). Can be labelled with Indium-111 for diagnostic investigation/imaging.

Mechanism Of Action and Pharmacodynamic Effects
Yttrium-90 conjugated anti-CD20 monoclonal antibody. Once bound to CD-20 +ve B-cells of the lymphoma, the beta particles act locally to destroy the cancerous cells.

Mechanism Of Action and Pharmacodynamic Effects

Yttrium-90 conjugated anti-CD20 monoclonal antibody. Once bound to CD-20 +ve B-cells of the lymphoma, the beta particles act locally to destroy the cancerous cells.

External links
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Drugs.com
European Medicines Agency (EMA)